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On December 14, 2012, the FDA approved Raxibacumab, the first monoclonal antibody
product developed under Project BioShield to achieve this milestone, and the first
biologic product to be approved through the FDA animal efficacy rule (or “Animal
Rule”). Raxibacumab is approved for the treatment of adult and pediatric patients
with inhalational anthrax due to Bacillus anthracis in combination with appropriate
antibiotic drugs and for prophylaxis of inhalational anthrax when alternative therapies
are not available or not appropriate. The developmental process required for approval of
Raxibacumab illustrates many of the challenges that product developers may encounter
when pursuing approval under the Animal Rule and highlights a number of important
regulatory and policy issues.
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THE ESTABLISHMENT OF ANTHRAX RESPONSE CAPABILITIES
FOR US GOVERNMENT
In 2004 Congress passed the Project Bioshield Act providing the organizational infrastructure
and money to acquire medical countermeasures for civilian use in the event of a bioterrorist
attack. Medical countermeasure development and procurement is managed by an interagency
body known as the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE),
including the Biomedical Advanced Research and Development Authority (BARDA) responsible
for the late-stage development of medical countermeasures. The priorities for countermeasure
development are established in accordance with provisions of the Project BioShield Act of 2004
with the Department of Homeland Security (DHS) determining which agents present “a material
threat against the United States population sufficient to affect national security.” The establishment
of a material threat is required for the Department of Health and Human Services (HHS) to pursue
countermeasure development using funds available under Project BioShield for the development
and procurement of medical countermeasures for the U.S. Strategic National Stockpile (SNS).
Anthrax, and in particular anthrax disease caused by inhalation of anthrax spores, was designated
a material threat by DHS.
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DEVELOPMENT OF RAXIBACUMAB FOR
ANTHRAX TREATMENT
As a result of the anthrax attacks in 2001, 11 people developed
inhalational anthrax, and despite intensive care including
treatment with multiple antibiotics, five of them died. Although
this mortality rate of 45% was lower than the 90% rate observed
historically, the high mortality resulting from this attack suggests
that antibiotic therapy alone is insufficient for the treatment of
such patients (Inglesby et al., 2002; Holty et al., 2006). In a
concerted attack with an outdoor release of anthrax modeling
suggests that large numbers of people would be exposed
with a substantial fraction developing symptomatic inhalational
anthrax, even in the setting of a prompt public health response
(Jernigan et al., 2001).
Antibiotics can be used to treat anthrax infection by reducing
bacteremia. However, since antibiotics have no direct effect
on toxins they cannot address the toxemia that is responsible
for the majority of the morbidity and mortality associated
with anthrax infection (Inglesby et al., 2002). In humans, as
well as animals, inhalational anthrax disease occurs following
inhalation of Bacillus anthracis spores, which germinate within
macrophages as they travel to the draining mediastinal lymph
nodes of the lung. Multiplication of the bacteria results in
a high organism count in the blood, production of bacterial
toxins, and the rapid onset of septicemia (Cote et al., 2011).
Although the bacterial replication (bacteremia) can be controlled
by administration of appropriate antibiotics, the bacterial toxin
exerts deleterious effects on the cells within the body, resulting in
substantial pathology and high mortality in infected individuals.
If the toxin reaches sufficient levels in an individual, controlling
bacterial replication with an antibiotic will not be sufficient to
affect the clinical outcome of the patient (Chitlaru et al., 2011).
Medical treatments against anthrax, such as antibiotics,
provide time for the host to mount an effective immune response
to clear the bacteria. All survivors of the 2001 anthrax attacks
developed an immune response to the anthrax toxin by day 28
after exposure (Wright et al., 2010). There is an FDA-licensed
anthrax vaccine, Anthrax Vaccine Adsorbed (AVA) (http://www.
fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/
ucm133822.htm), which works by inducing an immune response
primarily to the protective antigen component of anthrax
toxin. Once subjects produce this antibody, they are protected
against the effects of anthrax. However, vaccination is not an
effective stand-alone therapy after infection since anthrax disease
progresses rapidly and is fatal long before the time required to
generate an immune response from vaccination. Immunization
against anthrax requires multiple doses of vaccine and more
than 2 months to induce protective titers of antitoxin antibody
(Wright et al., 2010).
Immediately after the anthrax attacks in September and
October of 2001, Human Genome Sciences, Inc. (HGS)
embarked on a development program to produce a monoclonal
antibody to treat inhalational anthrax. The product of this
effort, Raxibacumab, is a human recombinant monoclonal
antibody that is administered by the intravenous route, resulting
in the rapid delivery of a PA-targeted antitoxin to patients.
At the approved dosage, Raxibacumab halts the deleterious
effects of toxin, providing time to “bridge the gap” for
patients until endogenous antibodies are produced and immunity
acquired. Antitoxin therapy treats the toxemia component
of anthrax infection that antibiotics cannot address (Migone
et al., 2009; Raxibacumab for anthrax, 2013). The efficacy
of Raxibacumab was demonstrated by its ability to improve
survival after lethal aerosol challenges of anthrax in two
animal models, New Zealand White rabbits and cynomologus
macaque nonhuman primates. In both models, Raxibacumab
treatment after exposure to aerosolized anthrax led to a higher
percentage of survival compared to untreated animals when
administered early in the disease, before symptoms develop,
as well as later, when the disease has progressed to systemic
infection (Mazumdar, 2009; Migone et al., 2009; Corey et al.,
2013).
In December 2012, the United States Food and Drug
Administration (FDA) approved Raxibacumab for the treatment
of and prophylaxis against inhalational anthrax (http://
www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/uc
m332341.htm). Also in 2012, HGS was acquired by
GlaxoSmithKline (GSK), which assumed the product license
and the responsibility for post marketing commitments and
production of Raxibacumab. Raxibacumab was shown to be
safe at the approved dose (40mg/kg) through clinical studies in
more than 300 healthy adults including 43 individuals receiving
a double dose (Subramanian et al., 2005; Migone et al., 2009).
REGULATORY PATH UNDER FDA’S
ANIMAL RULE
In order to provide a regulatory path for the evaluation of
medical countermeasures against biological threats the FDA
published in 2002 a regulatory guideline, “Evidence Needed to
Demonstrate Effectiveness of New Drugs When Human Efficacy
Studies Are Not Ethical or Feasible,” which was updated in 2015
(21 CFR 601, Subpart H; Food and Drug Administration, 2002)
(Animal Rule, 2015). This guideline, known as the “Animal Rule”,
described a regulatory pathway that has been used to support
the development of medical countermeasures against chemical,
biological, radiological, or nuclear (CBRN) threats. Raxibacumab
is the first new drug to receive approval under the Animal Rule.
The “Animal Rule” describes a process to determine the
efficacy of a medical countermeasure, such as Raxibacumab,
by performing pivotal trails in animals in lieu of clinical trials
in humans. The studies must address the four criteria for
demonstration of efficacy under the Animal Rule:
The Product has a Well-understood
Mechanism of Action against a Target with
Known Pathophysiology
The mechanism of anthrax toxin toxicity has been extensively
studied in vitro and the role of protective antigen (PA) in anthrax
disease is well-documented. In vitro studies demonstrate that
Raxibacumab binds PA with high affinity and interferes with the
binding of PA to its receptor thereby preventing the killing of
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murine and human macrophages by anthrax toxins (Mazumdar,
2009; Chen et al., 2011). Further in vivo studies in the rat, rabbit,
and cynomolgus macaque monkey demonstrated that treatment
with Raxibacumab provides protection from the lethal effects of
anthrax toxins leading to survival of infected animals (Cui et al.,
2005; Mazumdar, 2009; Migone et al., 2009; Corey et al., 2013).
Demonstration of Benefit in More Than
One Animal Species, Unless a Single
Species Represents a Sufficiently
Well-characterized Model to Predict
Response in Humans
HGS demonstrated the efficacy of Raxibacumab in both the New
ZealandWhite rabbit and cynomolgus macaque monkey anthrax
inhalation models. Both models were considered to provide
predictive value on the efficacy of anthrax treatments since in
both animal models the contribution of bacteremia and toxemia
to mortality were similar to that observed for humans. Pivotal
efficacy studies were conducted in both models (Migone et al.,
2009; Corey et al., 2013).
Use of an Efficacy Endpoint Relevant to
the Desired Outcome in Humans
The primary endpoint used in the animal studies, mortality,
is relevant to the outcome of the human disease, which is
highly lethal. In both rabbits and monkeys exposed to a target
anthrax spore challenge of 200 × lethal dose (LD50) almost
100%mortality was observed. Treatment of exposed animals with
Raxibacumab provided statistically significant improvement in
survival rates and in those animals that died, an extended time
to death.
In the pivotal rabbit efficacy studies, none of the animals in the
control groups (rabbit or nonhuman primate) challenged with
200 LD50 aerosolized anthrax spores survived.When rabbits were
challenged with 200 LD50 aerosolized anthrax spores and treated
with Raxibacumab 44.4% of animals treated with 40mg/kg
survived (p = 0.0029). Likewise, in the pivotal study with
nonhuman primates, 64.3% (p = 0.0007) of those treated with
40mg/kg survived. These results and the details of the challenge
model are presented in the cited reference (Migone et al., 2015).
One of the outcomes of the Vaccines and Related Biological
Products Advisory Committee (VRBPAC) meeting on
Raxibacumab was an FDA request to investigate the concomitant
use of the antitoxin with antibiotics, the present standard of
care for anthrax disease. The Agency wanted to determine
if co-administration of antitoxin would affect the efficacy
and pharmokinetic (PK) parameters of antibiotics and to
determine if the addition of Raxibacumab to antibiotic treatment
would provide an “added benefit” in increased efficacy. Co-
administration of Raxibacumab did not alter the efficacy of
levofloxacin (rabbits) or ciprofloxacin (nonhuman primates)
administered at recommended human doses (Migone et al.,
2009; Corey et al., 2013). Also, a clinical trial demonstrated
that the PK parameters of ciprofloxacin were unaffected with
concomitant use of Raxibacumab.
The demonstration of “added benefit” was more problematic
since early administration of antibiotics resulted in nearly 100%
survival in both the rabbit and nonhuman primate model, thus
making it very difficult to demonstrate additional value with
Raxibacumab use. To accomplish this, a “delayed treatment”
model was developed in which antibiotic treatment was delayed
so that the survival rate of exposed animals resembles the rate
observed for humans during the 2001 anthrax attacks (∼55%
rather than the survival rate of close to 100% for animals treated
when systemic anthrax disease was detected).
A delayed treatment study in the New Zealand White
rabbit model was used to support regulatory evaluation of
Raxibacumab. In this study treatment with the antibiotic
levofloxacin was delayed until 84 h post-exposure at which time
42% of the animals remained alive. The remaining animals were
randomized into two groups for treatment with levofloxacin or a
combination of Raxibacumab and levofloxacin. The survival rate
for animals treated with levofloxacin was 65% (24/37) compared
to 82% (32/39) of the rabbits in the treatment group receiving
levofloxacin and Raxibacumab. The difference in the survival
did not reach the p = 0.05 level of statistical significance
(p = 0.07) however the November 2, 2012 Anti-Infective
Drugs Advisory Committee voted overwhelmingly that these
results demonstrated the co-administration of Raxibacumab and
antibiotics would provide clinical benefit.
Pharmacokinetic Data that Allow
Translation of Effective Animal Doses to
Recommended Human Doses
In order to be confident that the efficacy results in animal models
are predictive of the countermeasure efficacy in humans the FDA
requires demonstration that the exposure levels of the drug in
humans meets or exceeds the exposure level that is effective
in the animal model. The PK data for Raxibacumab have been
acquired in both uninfected and anthrax infected rabbits and
cynomolgus monkeys. The PK data for humans was determined
from clinical trials including single and repeat dosing as well
as co-administration with antibiotics. The PK parameters of the
approved dose (40mg/kg) in humans were acceptable for FDA
approval.
SAFETY
Although efficacy is evaluated through animal models under
the FDA Animal Rule, safety is demonstrated through well-
monitored clinical trials. Considering the indicated use of
Raxibacumab as a therapeutic, the FDA required a safety database
of over 300 healthy human volunteers before approval. Adverse
events (AEs) were generally mild to moderate and did not
occur at a rate that was different from that observed among
placebo-treated subjects. A low incidence of mild to moderate
rash was observed in some subjects. These rashes were transient
and resolved without medication or with oral diphenhydramine.
Concomitant administration of Raxibacumab with ciprofloxacin
did not alter the safety or PK of either antibiotic or Raxibacumab
(Subramanian et al., 2005).
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POST MARKETING REQUIREMENT AFTER
THE LICENSURE
Based on the human safety data and the animal efficacy study
results, the US FDA approved Raxibacumab under the Animal
Rule for the treatment of adult and pediatric patients with
inhalational anthrax due to B. anthracis in combination with
appropriate antibiotic drugs, and for prophylaxis of inhalational
anthrax when alternative therapies are not available or are not
appropriate. Because efficacy data for product evaluation are
collected from animal models, one of the requirements for
products licensed under the Animal Rule is a post-marketing
commitment from the product sponsor to collect efficacy and
safety data post approval when the product is used in humans
to treat anthrax. In anticipation of Raxibacumab deployment
and use, GSK has submitted a field study protocol to the
FAD to evaluate the effectiveness, pharmacokinetics and safety
of Raxibacumab use for B. anthracis infection in the United
States. This is an open-label, single arm, study to evaluate
the clinical course (including survival), safety and PK in men,
women, and children of all ages exposed to B. anthracis
and treated with Raxibacumab as part of their clinical care
(https://clinicaltrials.gov/ct2/show/NCT02177721). The protocol
applies to circumstances where Raxibacumab is deployed to
treat individual cases of anthrax as well as an emergency
where mass distribution of Raxibacumab may be required. Once
Raxibacumab is dispatched by CDC, the field study will be
rapidly implemented to collect important clinical and PK data
on Raxibacumab in the midst of a public health emergency.
The study data will be used to confirm the efficacy and safety
of Raxibacumab and further inform patient care and treatment
choices for management of anthrax.
GSK also has a post-marketing commitment to evaluate the
effect of concomitant administration of Raxibacumab on the
activity of the licensed anthrax vaccine BioThrax R© when used
under conditions of post-exposure prophylaxis. In 2002, the CDC
recommended use of BioThrax R© in conjunction with antibiotics
in the post-exposure-prophylaxis setting, with administration of
the vaccine at 0, 2, and 4 weeks post exposure (Wright et al.,
2010). The FDA was concerned with the ability of the vaccine
to elicit a protective immune response in a scenario where
antitoxin and vaccine were co-administered to individuals during
an anthrax emergency. Since the primary antigen in Biothrax R© is
PA, it is possible that concurrent administration of BioThrax R©
and Raxibacumab would result in Raxibacumab binding the PA
from BioThrax R©, leading to a reduced immune response to the
vaccine.
To satisfy this post-marketing commitment GSK is executing
a clinical study designed to detect the effect of Raxibacumab on




The approval of Raxibacumab represents the first time a
monoclonal antibody product was evaluated for efficacy under
the FDA Animal Rule. The low number of inhalational anthrax
cases made it impossible to demonstrate efficacy using traditional
regulatory pathways and human clinical trials. Therefore, the
FDA is forced to estimate effectiveness of a product by “bridging”
from efficacy results obtained in animal models. The need
to build a convincing body of data demonstrating efficacy is
more complicated than the traditional method of demonstrating
efficacy through clinical trials or epidemiological results. The lack
of clear clinical efficacy data forces the development pathway into
an iterative process with significant lead time in animal model
development and characterization prior to proof of concept
or pivotal efficacy studies. The inability to perform clinical
trials usually means that additional experiments are required to
address uncertainties that arise during the development pathway.
For example, the results from initial animal efficacy experiments
led to reviewers’ questions that required additional numerous
studies to establish the “delayed treatment” model to investigate
added benefit and a series of studies with intensive pathological
characterization to determine the cause of the higher incidence
of brain lesions in animals that died after treatment with
Raxibacumab. These studies added 2 years and over $10 million
dollars to the developmental pathway. Also, the lack of clinical
evidence for efficacy means there are significant post-marketing
commitments to ensure data collection in the event the products
are used in humans during an anthrax emergency.
It is difficult to compare the cost and time for product
development under the Animal Rule to that using the traditional
pathways relying on human clinical trials. The studies needed
to support early development of Raxibacumab were supported
by Human Genome Science internal resources before transition
to BARDA in 2007. Support from NIH was also instrumental
in the characterization of the aerosol challenge animal model
and in the development of critical assays for the pivotal trials.
Using a rough estimate it appears that the time required
for product development and the cost associated with this
development is not vastly different from that of a product using
traditional regulatory pathways. The ability to develop medical
countermeasures using the Animal Rule, however, provides an
enormous benefit to the public health community in preparation
for a biological attack. In the absence of the Animal Rule,
anthrax countermeasures would be under IND status, making
the deployment and use of countermeasures difficult in a public
health emergency.
CONCLUSION
Since the approval of Raxibacumab, two other medical
countermeasures supported by BARDA, heptavalent Botulism
Antitoxin (hBAT), and Anthrax Immune Globulin (AIG), were
also approved, and three other medical countermeasures are in
late stage development for evaluation using the Animal Rule.
The experience gained through the Raxibacumab approval was
beneficial in the design of approaches for the evaluation of
the other products under the Animal Rule. In 2014 the FDA
published a draft guidance entitled Product Development Under
the Animal Rule to replace the version published in 2009. This
revision covers the issues for product development under the
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Animal Rule including new sections on study conduct, data
quality, data integrity, vaccine development, the development
of cellular and gene therapies, general expectations for animal
studies, the types of animals used in investigations, animal care,
study reports, and natural history studies.
As product developers and the FDA continue to use the
Animal Rule as a mechanism for efficacy evaluation, its role
will continue to evolve. The most important lesson BARDA
learned from the approval of Raxibacumab is that it is essential to
engage the FDA review division early and often throughout the
drug development process. Since evaluation of efficacy under the
Animal Rule is an iterative process requiring a substantial body
of data the best means of avoiding delays is frequent and open
communication between sponsors and FDA. Although there are
significant challenges associated with the evaluation of products
using the Animal Rule since each product development process
will present unique problems determined by the type of threat
agent, the availability of well-characterized animal models, and
the clarifying studies required during product evaluation this
regulatory mechanism allows the USG to be prepared to deploy
in an emergency products with a high likelihood of efficacy that
have been evaluated using the highest standards for safety and
manufacturing using goodmanufacturing practices as ensured by
the FDA.
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